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Introduction: This nonrandomized study aimed to identify the
optimal dose of every-3-week (q3w) and weekly nab-paclitaxel plus
q3w carboplatin as first-line therapy in patients with advanced
non-small cell lung cancer (NSCLC) for a phase 3 trial.
Methods: Previously untreated patients with advanced NSCLC
enrolled sequentially into seven cohorts (25 patients/cohort, N 
175). Cohorts 1 to 4 and 5 to 7 received nab-paclitaxel q3w and
weekly, respectively. Patients were evaluated for efficacy and safety.
Results: The most common treatment-related  grade 3 adverse
events were neutropenia (60%), neuropathy (19%), fatigue (9%),
and thrombocytopenia (29%) (no grade 4 neuropathy or fatigue). A
100 mg/m2 weekly nab-paclitaxel produced less serious adverse
events than other doses/schedules. Response rate (RR) was greater
in the weekly versus q3w cohorts (47% vs. 30%). Median progres-
sion-free survival (PFS) ranged from 4.8 to 6.9 months, and overall
survival (OS) ranged from 8.3 to 15.0 months (all cohorts). Patients
receiving 100 mg/m2 weekly nab-paclitaxel achieved 48% RR with
6.2 and 11.3 months of PFS and OS, respectively. In a retrospective
analysis, patients with nonsquamous cell carcinoma receiving
weekly nab-paclitaxel had significantly improved RR (59.4% vs.
23.5%, respectively, p 0.003), and2 months longer PFS and OS
compared with q3w schedule. In patients with squamous cell carci-
noma, the q3w schedule significantly increased PFS by 3 months
(p  0.014) and OS by 2 months (no difference in RR) compared
with the weekly schedule.
Conclusion: nab-Paclitaxel plus carboplatin is an effective therapy
for advanced NSCLC. Based on favorable efficacy and safety
profiles, a phase 3, randomized, multicenter study comparing 100
mg/m2 weekly nab-paclitaxel plus q3w carboplatin to solvent-based
paclitaxel plus carboplatin has enrolled patients.
KeyWords: nab-Paclitaxel, Abraxane, Taxane, NSCLC, Antitumor
activity.
(J Thorac Oncol. 2010;5: 852–861)
The most commonly used taxane combination treatment forpatients with advanced non-small cell lung cancer
(NSCLC) is carboplatin plus solvent-based paclitaxel.1,2 Sol-
vent-based paclitaxel 175–225 mg/m2 every-3-week (q3w)
combined with every-3-week carboplatin area under the
curve (AUC)  6. q3w demonstrated a 17 to 32% overall
response rate (ORR) in patients with advanced NSCLC.3–6
However, the Cremophor EL excipient in solvent-based pac-
litaxel raises major safety and efficacy concerns. Emerging
data indicated that Cremophor EL contributes to severe tox-
icities, including hypersensitivity reactions and peripheral
neuropathy, and entraps paclitaxel in micelles, thus reducing
its availability to tumor cells.7,8 Despite several studies that
compared various treatments of patients with advanced
NSCLC, lung cancer is still the leading cause of cancer death,
and the 5-year relative survival rate for stage IV NSCLC is
only 2%.9 Because of the safety and efficacy limitations of
current therapy options, there is a critical need for safe
chemotherapy agents with improved antitumor activity.
A novel paclitaxel formulation, nanoparticle albumin-
bound (nab-) paclitaxel (Abraxane; Abraxis Bioscience, Los
Angeles, CA) can be administered safely at higher doses than
doses used for solvent-based paclitaxel,10 and it produced
excellent antitumor activity in taxane-refractory metastatic
breast cancer patients.11 In a phase 3 trial, q3w nab-paclitaxel
showed increased efficacy compared with q3w solvent-based
paclitaxel.12 Consistent with these results, in a phase 2 study,
nab-paclitaxel 260 mg/m2 q3w demonstrated single-agent
activity in first-line patients with advanced NSCLC, produc-
ing an ORR of 16% in 43 patients with median time to
progression (TTP) and overall survival (OS) of 6 and 11
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months, respectively.13 These efficacy results compared fa-
vorably with a phase 3 trial with solvent-based paclitaxel
monotherapy (16% ORR, but only 3.9 and 6.8 months of TTP
and OS, respectively),14 or combination therapy with solvent-
based paclitaxel plus carboplatin (17% ORR, and 3.1 and 8.1
months of median TTP and OS, respectively).6 In addition, an
outstanding safety profile of nab-paclitaxel was observed; no
grade 4 toxicities were reported. Furthermore, nab-paclitaxel
monotherapy (125 mg/m2) administered weekly on days 1, 8,
and 15 (3 of 4 weeks) as first-line treatment for patients with
advanced NSCLC further increased efficacy compared with
the q3w monotherapy study, producing 30% ORR with 5 and
11 months of median TTP and OS, respectively.15
Given the favorable efficacy and safety profile of nab-
paclitaxel compared with solvent-based paclitaxel, this study
was conducted to identify the optimal dose of nab-paclitaxel
plus carboplatin AUC  6 q3w as first-line therapy in
patients with advanced NSCLC. This phase 2 study was
designed to provide sufficient efficacy and safety data to
possibly permit the planning of a subsequent phase 3 trial. In
addition, a retrospective histologic analysis was conducted to
identify whether efficacy outcomes were different in
nonsquamous (adenocarcinoma and large cell carcinoma)
versus squamous cell carcinoma subtypes of NSCLC.
PATIENTS AND METHODS
This study was conducted at 13 investigational centers
in Russia, between March 15th, 2005, and June 1, 2007. The
protocol and all related materials were approved by the
Independent Ethics Committees of the participating medical
institutions. This study was conducted in accordance with the
World Medical Association Declaration of Helsinki and
Good Clinical Practice, Guidelines of the International Con-
ference on Harmonization. Written informed consent was
obtained from all patients before study-related tests were
carried out.
Patients
Eligible patients included men and nonpregnant, non-
lactating women, at least 18 years of age, with histologically
or cytologically confirmed stage IIIB or IV NSCLC with
pleural effusion or evidence of inoperable local recurrence or
metastasis, and no other concurrent malignancy. Patients had
measurable disease as defined by the RECIST guidelines.16
Patients had no previous treatment for metastatic disease, had
a life expectancy of more than 12 weeks, and an Eastern
Cooperative Oncology Group performance status of 0 or 1.
Patients were required to have adequate hematologic, hepatic,
and renal function.
Patients were excluded from the study if they had
evidence of active brain metastasis, any other clinically
serious concurrent illness, or if they received radiotherapy or
chemotherapy in the previous 4 weeks. Patients with periph-
eral neuropathy greater than grade 1 (defined according to the
National Cancer Institute Common Terminology Criteria for
Adverse Events v3.0) or a history of allergy or hypersensi-
tivity to either of the study drugs were also excluded.
Study Design
This multicenter, open-label, phase 2 study evaluated
the safety and efficacy of q3w or weekly nab-paclitaxel
followed by carboplatin AUC  6 q3w in patients with
advanced NSCLC. Patients were sequentially enrolled in four
q3w cohorts and three weekly cohorts of increasing dose
levels of nab-paclitaxel (25 patients per cohort) (Figure 1).
This sample size (n  25 per cohort) was anticipated to
provide sufficient data to characterize the safety and to assess
the efficacy of the regimens at each dose level. Patients in
cohorts 1 to 4 received nab-paclitaxel q3w at successively
higher dose levels: 225 mg/m2 (the highest dose typically
used for solvent-based paclitaxel), 260 mg/m2 (the dose of
nab-paclitaxel approved for the treatment of patients with
metastatic breast cancer), 300 mg/m2 (the maximal tolerated
dose of nab-paclitaxel in a q3w schedule), and 340 mg/m2 (an
approximately 50% increase over the highest used solvent-
based paclitaxel dose of 225 mg/m2). After the emergence of
promising weekly data, three additional cohorts were added,
in which patients received various weekly regimens of nab-
paclitaxel. Patients in the first weekly regimens (cohort 5)
received nab-paclitaxel 140 mg/m2 weekly for 2 weeks (on
days 1 and 8 of a 21-day cycle), followed by a week of rest.
This schedule matched the dose intensity in an earlier study
of nab-paclitaxel in NSCLC.15 Cohort 6 received a lower
weekly dose (100 mg/m2) administered weekly without a
break (on days 1, 8, and 15 of a 21-day cycle), providing
a planned dose intensity (100.0 mg/m2/wk) comparable
with that of cohort 5 (93.3 mg/m2/wk). Cohort 7 also
received a weekly dose (125 mg/m2) administered weekly
without a break (on days 1, 8, and 15); the dose intensity
(125 mg/m2/wk) represented a 25% increase in planned
dose intensity over cohort 6.
FIGURE 1. nab-Paclitaxel dosing schedule. All patients also
received q3w carboplatin area under the curve  6. nab-
paclitaxel, nanoparticle albumin-bound paclitaxel; q3w, ev-
ery-3-week.
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Patients received treatment on an outpatient basis. nab-
Paclitaxel was given as a single 30-minute intravenous infu-
sion, without premedication, followed by carboplatin as a
30-minute infusion at AUC  6 calculated using the Calvert
formula.17 Patients continued receiving treatment in the ab-
sence of disease progression or unacceptable toxicity.
Efficacy and Safety Endpoints
The primary efficacy endpoint of this study was the
percentage of patients who achieved an objective con-
firmed complete or partial overall response (CR or PR,
respectively). Secondary efficacy endpoints were to eval-
uate stable disease (SD) for 16 weeks, progression-free
survival (PFS), and OS.
The safety endpoints were the incidence of treatment-
related adverse events (AEs), laboratory abnormalities, seri-
ous AEs, and incidence of patients experiencing dose modi-
fications, dose interruptions, and premature discontinuation
of study drug.
Assessments
All patients who received at least one dose of nab-
paclitaxel and carboplatin (treated population) were evaluated
for efficacy. Response assessments were performed every
third cycle, that is, every 9 weeks. All measurable lesions up
to a maximum of five lesions per organ and 10 lesions in
total, representative of all involved organs, were identified as
target lesions and measured and recorded at baseline. Re-
sponse rates (RRs), SD 16 weeks, and PFS were evaluated
based on RECIST. Phone follow-up or review of survival
records were conducted monthly for 6 months and every 3
months thereafter for 18 months (total of 24 months).
Treatment-related AEs in the entire patient population
were reported through the end of study or 30 days after the
end of treatment, whichever was longer. Nonhematologic
AEs were reported as treatment-related AEs graded using
National Cancer Institute Common Terminology Criteria for
Adverse Events v3.0. The median time to improvement of at
least 1 grade level was determined for severe ( grade 3)
peripheral neuropathy. Time to improvement was defined as
the time from the first occurrence of grade 3 peripheral
neuropathy to improvement of at least to grade 2. Laboratory
analyses to determine complete blood counts and serum
chemistries were performed in a central laboratory (Pivotal
Laboratories Ltd., York, UK).
Statistical Methods
The primary and secondary endpoints were summa-
rized descriptively, and 2-sided 95% confidence intervals
(CIs) are presented. Within histologic subtypes of NSCLC,
differences between weekly and q3w treatments for RR and
disease control rate (DCR; CR PR SD16 weeks) were
compared using 2 test, and PFS and OS comparisons were
analyzed using log-rank test.
RESULTS
Patients
A total of 175 patients were enrolled in the study in
successive cohorts of 25 patients to each of seven treatment
groups. Patient baseline characteristics are described in Table
1. The patient population was predominately men (81%), and
all patients were whites.
Patient Disposition
All enrolled patients received at least one dose of
treatment and were evaluated for all of the study endpoints.
All 175 (100%) patients have discontinued therapy, mostly
due to progressive disease (45%), unacceptable toxicity with-
out progressive disease (22%), patient discretion (22%), or
other (11%), including AEs not related to study drug or
investigator discretion. Treatment was permanently discon-
tinued for unacceptable toxicity in 24% (cohort 1), 16%
(cohort 2), 24% (cohort 3), and 44% (cohort 4) of patients in
the q3w cohorts and in 24% (cohort 5), 8% (cohort 6), and
28% (cohort 7) of patients in the weekly cohorts. In partic-
ular, the most common AEs that led to treatment discontin-
uation were thrombocytopenia and peripheral neuropathy in
the q3w cohorts, and thrombocytopenia and neutropenia
in the weekly cohorts. Only patients in the q3w cohorts
received prior chemotherapy; two (2%) patients had neoad-
juvant, and one patient had adjuvant therapy. No patients
received prior therapy for metastatic disease.
One hundred sixty-six of 175 treated patients had iden-
tified nonsquamous or squamous cell carcinoma histology
(Table 1) and were included in the retrospective efficacy
analysis (Table 3). Of the 100 patients receiving the q3w
regimens, 31 (31%) patients had adenocarcinoma and 3 (3%)
had large cell carcinoma (total of 34 34% patients with
nonsquamous cell carcinoma), 59 (59%) patients had squa-
mous cell carcinoma, and 7 (7%) patients had other (poorly
differentiated or nondifferentiated) histology. Of the 75 pa-
tients receiving the weekly regimens, 32 (43%) patients had
adenocarcinoma (no large cell carcinoma), 41 (55%) patients
had squamous cell carcinoma, and 2 (3%) patients had other
histology.
Efficacy Results
Primary Analysis
ORR ranged from 24 to 56% among the seven cohorts
(Table 2). In general, there was a trend for improved RR in
the weekly cohorts compared with the q3w cohorts. In the
weekly cohorts, ORR ranged from 36% in the 125 mg/m2 to
56% in the 140 mg/m2 weekly cohort; in the q3w cohorts,
ORR ranged from 24% in the 260 and 300 mg/m2 cohorts to
40% in the 225 mg/m2 cohort. There was no apparent direct
dose proportional relationship observed in ORR across the
q3w or weekly cohorts in terms of nab-paclitaxel dose.
Similar to ORR, DCR showed a wide range among the seven
dose cohorts spanning from 32 to 64%, but there was no
difference between weekly (48–64%) and q3w treatments
(32–60%).
Median PFS was similar between q3w and weekly
treatments. Median PFS ranged from 4.8 to 6.9 months in the
q3w cohorts and 5.6 to 6.4 months in the weekly cohorts
(Table 2 and Figure 2). Median OS was also similar between
the q3w and weekly cohorts, ranging from 8.3 to 14.6 months
in the q3w cohorts and 11.3 to 15.0 months in the weekly
cohorts (Table 2 and Figure 3).
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Retrospective Histologic Analysis
Patients with histologic confirmation of nonsquamous
cell carcinoma receiving weekly nab-paclitaxel (all adeno-
carcinoma cases) achieved better efficacy compared with the
q3w schedule (mostly 91% adenocarcinoma cases) (ORR:
59.4% vs. 23.5%, respectively, p  0.003), and 2 months
TABLE 1. Baseline Patient Demographics and Characteristics
nab-Paclitaxel Doses and Schedule (n  25 per C)
q3w
Weekly Days
1, 8 Weekly Days 1, 8, 15
C1 225 mg/m2 C2 260 mg/m2 C3 300 mg/m2 C4 340 mg/m2 C5 140 mg/m2 C6 100 mg/m2 C7 125 mg/m2
Men, n (%) 23 (92) 18 (72) 17 (68) 20 (80) 22 (88) 21 (84) 20 (80)
Age, mean yr 59.7 63.1 60.1 61.3 61.6 59.9 58.8
Range 43–75 48–81 41–81 37–75 47–81 34–78 37–79
Histology of malignancy
at diagnosis, n
(%)
Nonsquamous cell 9 (36) 7 (28) 9 (36) 9 (36) 10 (40) 9 (36) 13 (52)
Adenocarcinoma 8 (32) 7 (28) 9 (36) 7 (28) 10 (40) 9 (36) 13 (52)
Large cell 1 (4) 0 0 2 (8) 0 0
Squamous cell 11 (44) 18 (72) 14 (56) 16 (64) 15 (60) 16 (64) 10 (40)
Othera 5 (20) 0 2 (8) 0 0 0 2 (8)
Disease stage, n (%)
IIIB 10 (40) 8 (32) 4 (16) 3 (12) 4 (16) 4 (16) 7 (28)
IV 15 (60) 17 (68) 21 (84) 22 (88) 21 (84) 21 (84) 18 (72)
ECOG PS, n (%)
0 1 (4) 0 3 (12) 7 (28) 5 (20) 4 (16) 3 (12)
1 24 (96) 25 (100) 22 (88) 18 (72) 20 (80) 21 (84) 22 (88)
Preexisting peripheral
neuropathy, n (%)
Grade 0 23 (92) 23 (92) 24 (96) 21 (84) 25 (100) 24 (96) 25 (100)
Grade 1 2 (8) 2 (8) 1 (4) 4 (16) 0 1 (4) 0
a Poorly differentiated or nondifferentiated non-small cell lung cancer.
C, cohort; ECOG PS, Eastern Cooperative Oncology Group performance status; q3w, every-3-wk.
TABLE 2. Response Rates, Disease Control Rates, and Progression-Free and Overall Survival for All Treated Patients
nab-Paclitaxel Doses and Schedule (n  25 per C)
q3w
Weekly Days
1, 8 Weekly Days 1, 8, 15
C1 225 mg/m2 C2 260 mg/m2 C3 300 mg/m2 C4 340 mg/m2 C5 140 mg/m2 C6 100 mg/m2 C7 125 mg/m2
Overall response rate,
n (%)
10 (40) 6 (24) 6 (24) 8 (32) 14 (56) 12 (48) 9 (36)
95% CI 20.8–59.2 7.3–40.7 7.3–40.7 13.7–50.3 36.5–75.5 28.4–67.6 17.2–54.8
Complete response, n
(%)
0 1 (4) 0 0 0 1 (4) 1 (4)
Partial response, n (%) 10 (40) 5 (20) 6 (24) 8 (32) 14 (56) 11 (44) 8 (32)
Stable disease 16
Wk, n (%)
5 (20) 8 (32) 3 (12) 0 2 (8) 2 (8) 3 (12)
Disease control rate,a n
(%)
15 (60) 14 (56) 9 (36) 8 (32) 16 (64) 14 (56) 12 (48)
95% CI 40.8–79.2 36.5–75.5 17.2–54.8 13.7–50.3 45.2–82.8 36.5–75.5 28.4–67.6
Progression-free
survival, mo
6.9 6.5 5.3 4.8 5.6 6.2 6.4
95% CI 4.2–9.6 4.3–9.1 2.2–8.5 3.9–7.8 3.9–7.7 4.2–9.7 4.2–7.9
Overall survival, mo 10.7 12.2 8.3 14.6 12.0 11.3 15.0
95% CI 8.7–17.0 8.5–21.9 4.2–15.4 7.6–17.2 6.5–17.1 7.8–20.1 10.0–18.4
a Disease control rate  CR  PR  SD 16 wk.
C, cohort; CI, confidence interval; q3w, every-3-wk; CR, complete overall response; PR, partial overall response; SD, stable disease.
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longer PFS and OS compared with the q3w schedule (Figure
4A). Conversely, in patients with squamous cell carcinoma
receiving q3w versus weekly nab-paclitaxel, PFS signifi-
cantly increased by 3 months (p  0.014) and OS increased
by 2 months, with no difference in ORR (Figure 4B). In
particular, of the 59 patients in the q3w cohorts with squa-
mous cell carcinoma, 1 (2%) patient had CR, 20 (34%)
patients had a PR, and 9 (15%) patients had SD for 16
weeks (Table 3). In the weekly cohorts of patients with
squamous cell carcinoma (41 total), 16 (39%) patients had PR
(no CR occurred) and 3 (7%) patients had SD for16 weeks.
Of the 34 patients in the q3w cohorts with nonsquamous cell
FIGURE 2. Progression-free survival. A, Cohort 1 to 4, ev-
ery-3-week nab-paclitaxel dosing (top). B, Cohort 5 to 7,
weekly nab-paclitaxel dosing (bottom). C, cohort.
FIGURE 3. Overall survival. A, Cohort 1 to 4, every-3-week
nab-paclitaxel dosing (top). B, Cohort 5 to 7, weekly nab-
paclitaxel dosing (bottom). C, cohort.
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carcinoma, 8 (24%) patients had PR (no CR occurred) and 5
(15%) patients had SD for 16 weeks (Table 3). In the
weekly cohorts of patients with nonsquamous cell carcinoma
(32 total), 2 (6%) patients had CR, 17 (53%) patients had PR,
and 3 (9%) patients had SD for 16 weeks.
Treatment Exposure
In the q3w cohorts, the mean number of cycles admin-
istered was greater in the 225 mg/m2 (6.5 cycles) and 260
mg/m2 (6.7 cycles) cohorts than in the 300 mg/m2 (4.5
cycles) and 340 mg/m2 (4.6 cycles) cohorts. In the weekly
cohorts, the greatest mean number of cycles was administered
to the 140 mg/m2 dose group (6.4 cycles) followed by the 100
mg/m2 dose cohort (6.2 cycles), and the least mean number of
cycles was administered to the 125 mg/m2 dose group (5.0
cycles). The greatest mean cumulative dose of nab-paclitaxel
was delivered in the 260 mg/m2 q3w group (1685.8 mg/m2),
and the least mean cumulative dose delivered was in the 300
mg/m2 q3w group (1290 mg/m2).
The greatest mean dose intensity of nab-paclitaxel was
delivered in the 340 mg/m2 q3w group (95.99 mg/m2/wk),
and the least average dose intensity (mean value) of nab-
paclitaxel was delivered in the 225 mg/m2 q3w group (68.46
mg/m2/wk). Although the planned dose intensity was the
same in the 300 mg/m2 q3w (cohort 3) and 100 mg/m2
weekly (cohort 6) groups, the mean cumulative dose deliv-
ered was higher in cohort 6 (1541.8 mg/m2) compared with
cohort 3 (1290.0 mg/m2).
Safety Results
Primary Analysis
In general, all seven cohorts showed comparable safety
results, with the least severe AEs occurring in the 100 mg/m2
weekly cohort (Table 4). Seven probably or possibly treat-
ment-related deaths occurred: six in the q3w cohorts and one
in the weekly cohorts. Treatment-related hematologic  grade 3
AEs were neutropenia (60%), leukopenia (32%), thrombocy-
topenia (29%), and anemia (22%). In particular, with q3w
treatment (cohorts 1–4), grade 3 and 4 neutropenia occurred
in 33 and 22% of patients, respectively. With weekly treat-
ment (cohorts 5–7), grade 3 and 4 neutropenia occurred in 32
and 35% of patients, respectively. No febrile neutropenia
occurred during this study.
The most common treatment-related nonhematologic
grade 3 AE was peripheral neuropathy (19%), and no grade 4
event occurred. Nineteen of 33 patients (58%) with grade 3
peripheral neuropathy improved to grade 2 or better: 15 of 25
FIGURE 4. Efficacy results by his-
tologic subtypes of NSCLC. A,
Nonsquamous cell carcinoma
(top). B, Squamous cell carcinoma
(bottom). N/S, statistically nonsig-
nificant; q3w, every-3-week;
NSCLC, non-small cell lung
cancer.
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(60%) patients in the q3w cohorts and four of eight (50%) in
the weekly cohorts. Both q3w and weekly nab-paclitaxel
dosing produced a median time to peripheral neuropathy
recovery of 18 days (q3w: 95% CI, 15–34 days; weekly: 95%
CI, 8–24 days) (Table 5).
Sixty-four (64%) and 49 (65%) patients in the q3w and
weekly cohorts, respectively, had at least 1 cycle delay. Forty
(40%) patients in the q3w cohorts and 38 (51%) patients in the
weekly cohorts had at least 1 nab-paclitaxel dose reduction.
Hematologic toxicity was the most common reason for nab-
paclitaxel dose reductions (65 and 84% of patients with dose
reduction in the q3w and weekly treatments, respectively). Six
percentage and 16% of patients had a carboplatin dose reduction
in the q3w and weekly cohorts, respectively. There were no
nab-paclitaxel dose interruptions in the q3w and weekly cohorts,
and two patients had carboplatin dose interruptions in the q3w
cohorts because of hypersensitivity reaction.
Retrospective Histologic Analysis
Consistent with the primary analysis, regardless of
histology, all seven cohorts showed comparable safety
results. Treatment-related hematologic  grade 3 AEs in
patients with nonsquamous cell carcinoma (66 total pa-
tients) and squamous cell carcinoma (100 total patients)
were neutropenia (65 and 57%, respectively), leukopenia
(38 and 28%), thrombocytopenia (38 and 24%), and ane-
TABLE 3. Response Rates, Disease Control Rates, and Progression-Free and Overall Survival by Histologic Subtypes
nab-Paclitaxel Doses and Schedule (n  25 per C)
Q3w
Weekly Days
1, 8 Weekly Days 1, 8, 15
C1 225 mg/m2 C2 260 mg/m2 C3 300 mg/m2 C4 340 mg/m2 C5 140 mg/m2 C6 100 mg/m2 C7 125 mg/m2
Squamous cell carcinoma
histology
Overall response rate, n
(%)
5 (45) 5 (28) 5 (36) 6 (38) 8 (53) 5 (31) 3 (30)
95% CI 16.8–76.6 9.7–53.5 12.8–64.9 13.8–61.2 28.1–78.6 11.0–58.7 6.7–65.2
Complete response, n
(%)
0 1 (6) 0 0 0 0 0
Partial response, n (%) 5 (45) 4 (22) 5 (36) 6 (38) 8 (53) 5 (31) 3 (30)
Stable disease 16 wk,
n (%)
2 (18) 6 (33) 1 (7) 0 1 (7) 1 (6) 1 (10)
Disease control ratea, n
(%)
7 (64) 11 (61) 6 (43) 6 (37) 9 (60) 6 (38) 4 (40)
95% CI 35.2–92.1 38.6–83.6 16.9–68.8 13.8–61.2 35.2–84.8 13.8–61.2 12.2–73.8
Progression-free
survival, mo
8.1 8.4 5.3 6.0 5.0 4.5 4.2
95% CI 4.2–10.4 5.7–21.7 1.9–15.5 4.4–7.8 3.9–6.1 2.1–9.7 4.1–7.9
Overall survival, mo 13.2 12.2 8.0 15.1 9.4 12.6 10.9
95% CI 5.4–18.5 8.5–23.9 3.1–17.8 10.5–18.5 7.8–14.0 5.3–18.8 9.2–16.3
Nonsquamous cell
carcinoma
histology
Overall response rate, n
(%)
4 (44) 1 (14) 1 (11) 2 (22) 6 (60) 7 (78) 6 (46)
95% CI 13.7–78.8 0.4–57.9 0.3–48.2 2.8–60.0 29.6–90.4 50.6–100.0 19.1–73.2
Complete response, n
(%)
0 0 0 0 0 1 (11) 1 (8)
Partial response, n (%) 4 (44) 1 (14) 1 (11) 2 (22) 6 (60) 6 (67) 5 (38)
Stable disease 16 wk,
n (%)
1 (11) 2 (29) 2 (22) 0 1 (10) 1 (11) 1 (8)
Disease control rate,a n
(%)
5 (56) 3 (43) 3 (33) 2 (22) 7 (70) 8 (89) 7 (54)
95% CI 21.2–86.3 9.9–81.6 7.5–70.1 2.8–60.0 41.6–98.4 68.4–100.0 26.8–80.1
Progression-free
survival, mo
5.8 5.5 5.3 4.4 7.7 6.6 18.3
95% CI 4.0–9.6 2.5–10.2 3.5–7.0 3.7–8.7 3.5–15.9 5.7–17.0 4.6–18.3
Overall survival, mo 12.4 10.7 10.5 11.9 13.1 9.8 18.4
95% CI 10.3–21.0 7.3–22.0 7.3–25.1 4.4–22.3 4.8–18.4 7.8–11.3 15.0–18.4
a Disease control rate  CR  PR  SD 16 wk.
C, cohort; CI, confidence interval; q3w, every-3-wk; CR, complete overall response; PR, partial overall response; SD, stable disease.
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mia (21 and 23%). Seven (21%) and four (13%) patients
with nonsquamous cell carcinoma in the q3w and weekly
cohorts, respectively, had grade 3 peripheral neuropathy.
In patients with squamous cell carcinoma, 16 (27%) in the
q3w and 4 (10%) in the weekly cohorts had grade 3
peripheral neuropathy.
DISCUSSION
In this study, the combination of nab-paclitaxel plus
carboplatin AUC 6 q3w demonstrated antitumor activity in
all cohorts and was well tolerated. These results compare
favorably with data reported in a phase 3 trial in patients with
advanced NSCLC treated with the standard dose of solvent-
based paclitaxel plus carboplatin.6 In this study, patients
receiving 140 mg/m2 weekly nab-paclitaxel (cohort 5)
achieved the highest DCR among all doses tested, but they
also had more severe myelosuppression than those in other
cohorts. The 100 mg/m2 dose, although not showing the
highest DCR of all doses tested, provided the best clinical
benefit-risk ratio. Given the high cumulative dose delivered
TABLE 4. Most Common Treatment-Related  Grade 3 Adverse Events in 5% of Patients
Adverse Events, n (%)
nab-Paclitaxel Doses and Schedule (n  25 per C)
q3w
Weekly Days
1, 8 Weekly Days 1, 8, 15
C1 225 mg/m2 C2 260 mg/m2 C3 300 mg/m2 C4 340 mg/m2 C5 140 mg/m2 C6 100 mg/m2 C7 125 mg/m2
Neutropenia
Grade 3 8 (32) 9 (36) 9 (36) 7 (28) 8 (32) 9 (36) 7 (28)
Grade 4 8 (32) 6 (24) 3 (12) 5 (20) 11 (44) 7 (28) 8 (32)
Leukocytopenia
Grade 3 8 (32) 6 (24) 7 (28) 9 (36) 12 (48) 6 (24) 5 (20)
Grade 4 1 (4) 0 0 1 (4) 0 0 1 (4)
Peripheral neuropathy
Grade 3 3 (12) 4 (16) 6 (24) 12 (48) 2 (8) 2 (8) 4 (16)
Grade 4 0 0 0 0 0 0 0
Fatigue
Grade 3 3 (12) 1 (4) 4 (16) 3 (12) 1 (4) 0 4 (16)
Grade 4 0 0 0 0 0 0 0
Thrombocytopenia
Grade 3 7 (28) 5 (20) 5 (20) 5 (20) 5 (20) 4 (16) 5 (20)
Grade 4 3 (12) 1 (4) 2 (8) 1 (4) 3 (12) 1 (4) 4 (16)
Anemia
Grade 3 4 (16) 6 (24) 3 (12) 2 (8) 4 (16) 4 (16) 10 (40)
Grade 4 1 (4) 0 1 (4) 1 (4) 1 (4) 0 1 (4)
Myalgia
Grade 3 0 1 (4) 1 (4) 6 (24) 0 0 0
Grade 4 0 0 0 0 0 0 0
Arthralgia
Grade 3 0 1 (4) 1 (4) 2 (8) 0 0 0
Grade 4 0 0 0 0 0 0 0
C, cohort; q3w, every-3-wk.
TABLE 5. Time to Improvement of Peripheral Neuropathy
nab-Paclitaxel Doses and Schedule (n  25 per C)
q3w
Weekly Days
1, 8 Weekly Days 1, 8, 15
C1 225 mg/m2 C2 260 mg/m2 C3 300 mg/m2 C4 340 mg/m2 C5 140 mg/m2 C6 100 mg/m2 C7 125 mg/m2
Improved to grade 2, n (%) 2 (67) 4 (100) 2 (33) 7 (58) 1 (50) 2 (100) 1 (25)
Time to improvement, median
daysa
15.0 14.5 48.0 23.0 8.0 15.5 24.0
95% CI 9.0–21.0 6.0–34.0 6.0–48.0 17.0–66.0 — 13.0–18.0 8.0–24.0
a Time to improvement was defined as the time from the first occurrence of grade 3 peripheral neuropathy to improvement at least to a grade 2. Patients were followed up for
30 d from the time of the most recent occurrence.
C, cohort; CI, confidence interval; q3w, every-3-wk.
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and the excellent safety and efficacy profile of cohort 6, the
100 mg/m2 weekly nab-paclitaxel plus carboplatin AUC 
6 q3w combination was believed to be the optimal dosing
and schedule for phase 3 comparison in patients with
advanced NSCLC.
Although both q3w and weekly regimens were effec-
tive in patients with advanced NSCLC, weekly treatments
with nab-paclitaxel seemed to be associated with improved
clinical outcomes compared with q3w regimens. Patients who
received a weekly schedule of nab-paclitaxel had greater
ORR (range: 36–56%) than those who received q3w doses
(range: 24–40%). Conversely, PFS was similar for q3w
(range: 4.8–6.9 months) and weekly (range: 5.6–6.4 months)
regimens. Similarly, OS was not different between q3w
(range: 8.3–14.6 months) and weekly (range: 12.0–15.0
months) regimens.
Consistent with these results, a number of small studies
have also reported antitumor activity with nab-paclitaxel
combination therapy for the treatment of patients with
NSCLC. A phase 1 study with nab-paclitaxel plus carboplatin
administered to heavily pretreated patients with solid tumors,
including NSCLC, demonstrated that this combination was
active and well tolerated across a range of dosing schedules.18
Furthermore, in a phase 2 open-label trial in patients with
inoperable stage IIIB/IV NSCLC, first-line treatment of nab-
paclitaxel 100 mg/m2 weekly (3 of 4 weeks) plus carboplatin
every 4 weeks was safe and demonstrated 50% ORR and 6.3
months median TTP.19
The antitumor activity of nab-paclitaxel plus carbopla-
tin doublet therapy may, in part, be explained by the prefer-
ential intratumor paclitaxel accumulation through the novel
albumin-bound paclitaxel formulation. In preclinical studies,
not only higher intratumor concentration of nab-paclitaxel
versus solvent-based paclitaxel was observed but also mice
receiving nab-paclitaxel had increased CR, longer TTP, and
prolonged OS.20 An albumin-binding protein, secreted pro-
tein acidic and rich in cysteine (SPARC), is known to be
overexpressed in lung cancer and is a poor prognostic fac-
tor.21 Likely, the albumin-binding property of SPARC plays
a role in the increased paclitaxel availability to tumor cells
and may subsequently increase the efficacy of nab-paclitaxel.
The role of SPARC in the efficacy of nab-paclitaxel is
currently being evaluated in various clinical trials, including
a phase 3 trial in patients with advanced NSCLC.
In addition to improved antitumor activity, nab-pacli-
taxel administered weekly was associated with less serious
AEs than when administered q3w, with significant reductions
in the incidence of peripheral neuropathy, myalgia, arthralgia,
and alopecia. Even though this study combined nab-pacli-
taxel with carboplatin, time to improvement in peripheral
neuropathy was comparable (median: 18 days) with that
observed in a phase 3 study of monotherapy nab-paclitaxel in
patients with metastatic breast cancer (median: 22 days).12
Specifically, the incidence of peripheral neuropathy was low-
est in the 100 and 140 mg/m2 weekly cohorts, and in the 100
mg/m2 cohort, all severe neuropathy cases improved to grade
2 or better within 16 days.
Novel targeted therapies and chemotherapeutic agents
showed different efficacy in specific NSCLC subcategories,
in particular, for squamous cell carcinoma and adenocar-
cinoma.22 NSCLC subtypes not only arise from different
anatomic locations but also have distinct embryologic ori-
gins22 and, thus, are likely to have different drug transport
capabilities. Therefore, histologic characterization of NSCLC
has become increasingly important for targeted therapy to
maximize benefits of therapeutic agents and avoid adverse
side effects. In the present retrospective analysis, patients
with either histologic subtype have responded to treatments.
In particular, patients with histologic confirmation of
nonsquamous cell carcinoma receiving weekly nab-paclitaxel
(all adenocarcinoma cases) had improved efficacy outcomes
compared with q3w schedule (mostly adenocarcinoma cases,
91%), in terms of ORR, PFS, and OS. Conversely, patients
with squamous cell carcinoma receiving q3w nab-paclitaxel
had improved efficacy outcomes (PFS and OS) compared
with weekly schedule. The significance of these retrospective
observations cannot be elucidated in the context of this study.
In stage I to IIIA NSCLC tissues, squamous cell carcinomas
express higher levels of cyclins (proteins regulating cellular
proliferation) versus adenocarcinomas.23 However, because
of the scant information about the pharmacogenomic charac-
terization of stage IIIB and IV NSCLC histologic subtypes, it
is unclear which genes or proteins play a role in the differ-
ential efficacy outcome in this study. Future studies are
needed to elucidate the pharmacogenomics of the histologic
subtypes of advanced NSCLC.
In conclusion, this study demonstrated that nab-pacli-
taxel is an effective and safe therapy for NSCLC. In general,
100 mg/m2 weekly nab-paclitaxel combined with carboplatin
AUC  6 q3w is an optimal dose and schedule for the
treatments of advanced NSCLC. Based on the favorable
safety profile and the excellent antitumor activity of the low
weekly dose of 100 mg/m2 nab-paclitaxel, a large (N 1050)
phase 3, randomized, multicenter study comparing 100
mg/m2 nab-paclitaxel plus carboplatin AUC  6 q3w with
standard dose of solvent-based paclitaxel plus carboplatin has
been initiated and completed enrollment.
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